CarlaMarie(Lichtenberger)NesterMDMSA, FASN
Nephrology • Iowa City, IAProfessor of Internal Medicine and Pediatrics, University Iowa,Carver College of Medicine
Dr. Nester is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
285 Newton Road
5294 CBRB
Iowa City, IA 52241Phone+1 319-335-2214Fax+1 319-384-9616
Education & Training
University of North Carolina HospitalsFellowship, Nephrology, 2003 - 2007- University of North Carolina HospitalsFellowship, Pediatric Nephrology, 2003 - 2007
- University of North Carolina HospitalsResidency, Internal Medicine/Pediatrics, 1998 - 2002
Pennsylvania State University College of MedicineClass of 1998
Certifications & Licensure
IA State Medical License 2007 - 2025
NC State Medical License 1999 - 2007- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Nephrology
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Nephrology
Publications & Presentations
PubMed
- Extrarenal manifestations of atypical hemolytic uremic syndrome: a systematic review and meta-analysis.Kush Doshi, Abdel Yusuf, Christoph Licht, Olivia Boyer, Carla Nester
Pediatric Research. 2024-12-15 - 1 citationsAn expert discussion on the atypical hemolytic uremic syndrome nomenclature-identifying a road map to precision: a report of a National Kidney Foundation Working Group.Carla M Nester, David L Feldman, Richard Burwick, Spero Cataland, Shruti Chaturvedi
Kidney International. 2024-09-01 - 1 citationsDeveloping Therapies for C3 Glomerulopathy: Report of the Kidney Health Initiative C3 Glomerulopathy Trial Endpoints Work Group.Carla Nester, Dima A Decker, Matthias Meier, Shakil Aslam, Andrew S Bomback
Clinical Journal of the American Society of Nephrology. 2024-06-03
Press Mentions
Results from Clinical Trial of Iptacopan in C3GDecember 5th, 2024- Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGNOctober 26th, 2024
- Novartis Oral Fabhalta® (Iptacopan) Sustained Clinically Meaningful Results at One Year in Phase III C3 Glomerulopathy (C3G) TrialOctober 26th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
